Open AccessPerformance of the VERSANT ® HIV‐1 Resistance Assays (LiPA) for detecting drug resistance in therapy‐naive patients infected with different HIV‐1 subtypes
Author(s) -
Derdelinckx Inge,
Laethem Kristel,
Maes Bart,
Schrooten Yoeri,
Schouwer Kirsten,
Wit Stéphane,
Fransen Katrien,
García Ribas Sergio,
Moutschen Michel,
Vaira Dolores,
Zissis Georges,
Ranst Marc,
Wijngaerden Eric,
Vandamme AnneMieke
Publication year - 2003
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1016/s0928-8244(03)00240-2
Subject(s) - concordance , drug resistance , virology , biology , reverse transcriptase , population , human immunodeficiency virus (hiv) , protease , hiv drug resistance , drug naïve , hiv 1 protease , sida , drug , antiretroviral therapy , viral disease , immunology , viral load , medicine , polymerase chain reaction , microbiology and biotechnology , pharmacology , enzyme , bioinformatics , genetics , biochemistry , environmental health , gene
In this study we evaluated the performance of the VERSANT ® HIV‐1 Resistance Assays (LiPA) in detecting drug resistance in therapy‐naive HIV‐infected patients diagnosed in Belgium in 2000. We compared the results with population sequencing and found concordance to be in line with previous studies in treatment‐experienced patients (86.87% for reverse transcriptase (RT); 92.77% for protease (PRO)). Discordance was mainly due to indeterminate reactions on LiPA (8.45% for RT; 6.85% for PRO) and minor discordances (4.13% for RT; 0.25% for PRO). Major discordances were rare (0.46% for RT; 0.12% for PRO). Indeterminate reactions were significantly associated with strains belonging to non‐B subtypes.